----

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.1    |           “Affiliate” of a      party shall mean a corporation or other business entity controlled by,      controlling or under common control with, such party. For this purpose,      control of a corporation or other business entity shall mean direct or      indirect beneficial ownership of more than fifty percent (50%) of the      voting interest in, or a greater than fifty percent (50%) interest in the      equity of, such corporation or other business entity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1.2    |           “Analyte Specific      Reagent” or “ASR” shall mean      the finished, packaged and labeled assembly of a Licensed Product in the      form of assay components, purchased by commercial laboratories to test for      the detection and/or quantification of an analyte under the United States      Code of Federal Regulations, Title 21, Paragraphs 809.10, 809.30, 864.4010      and 864.4020.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1.3    |           “Change of      Control” means (a) the acquisition of a party by another      entity by means of any transaction or series of related transactions      (including, without limitation, any reorganization, merger or      consolidation) that results in the transfer of fifty percent (50%) or more      of the voting securities of such party, (b) a sale of all or      substantially all of the assets of a party, or (c) the acquisition by any      person or other entity (other than a party and its Affiliates or employee      benefit plans), including any person or group as defined in Paragraphs      3(a)(9) and 13(d), 14(d) and Rule 13d-5 of the Exchange Act of more than      fifty percent (50%) of the voting securities of such party; provided,      however, that no Change in Control shall occur by reason of (i) an initial      public offering, or (ii) a reorganization, merger, consolidation or sale,      the sole purpose of which is to change the state of a party’s      incorporation or to create a holding company that will be owned in      substantially the same proportions by the persons who held such party’s      securities immediately before suchtransaction. |

----

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.4    |             “Collaboration”      shall mean that term as it is defined in Paragraph 2.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.5    |             “Collaboration Term” means      the time period commencing upon the Effective Date and continuing until      the first to occur of the date three (3) years after such date or      completion of the research contemplated by the FDA Submission      Plan.                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.6    |             “Confidential      Information” shall mean the terms and conditions of this Agreement,      and all information developed by the parties pursuant to the Collaboration      and all other disclosed by one party to the other in writing and clearly      marked “Confidential” or, if communicated orally, specified as      confidential at the time of disclosure and confirmed in writing within      thirty (30) days after such oral communication and clearly marked      “Confidential”; provided, however, that Confidential Information shall not      include information that: |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |           1.6.1          is      already in the public domain, or on or after the Effective Date comes into      the public domain other than as a result of the wrongful disclosure by      either party to this Agreement;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |           1.6.2          is      already known to the recipient as evidenced by prior-dated written      documents already in the recipient’s possession, which documents were not      furnished by the other party to this Agreement;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |           1.6.3          is      disclosed to the other party by any third party having the right to make      that disclosure;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |           1.6.4          is      required by law to be disclosed in connection with the registration or      filing with, or approval or certification from any governmental agency or      body including, without limitation, the United States Food and Drug      Administration, provided that the information is not the inventive subject      matter of an unpublished patent application, or is required to be      disclosed to comply with the terms of contractual relationships and      provided that each party undertakes to use its best endeavors to maintain      to the maximum extent possible and to make any third parties to whom such      information is disclosed aware of the confidentiality of such information;      or |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |           1.6.5          can      be proven to have been independently developed by the party receiving the      information under this Agreement without the aid, application or use in      any way of Confidential Information received from the disclosing      party.                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.7    |             “FDA Submission      Plan” shall mean the plan for the Collaboration attached hereto as      Exhibit      C.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.8    |             “Field” shall      mean the use of a molecular diagnostic assay using the Licensed Prostate      Markers in in      vitro diagnostics relating to prostate cancer, including the      detection of the presence or risk of prostate cancer, or the selection of      therapy, or in a Research Application related to prostate      cancer.                                                                                                                                                                                                                                                                        |

----

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.9    |             “First Commercial      Sale” or “FCS” shall mean      the first time, except in the context of a clinical trial, Abbott      transfers title of Licensed Product to an independent third party for      monetary consideration or provides a Diagnostic Test Service using      Licensed Product to an independent third party for monetary      consideration.                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1.10   |             “IVD” shall mean      an assay which claims an intended use, and is approved by a governmental      regulatory body for sale, as an in vitro diagnostic      kit, and which is not an ASR or labeled for “Research Use Only”, including      an assay that is CE Marked.                                                                                                                                                                                                                                                |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1.11   |             “Joint      Inventions” shall mean all new inventions jointly made, by the      parties as part of the Collaboration.                                                                                                                                                                                                                                                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1.12   |             “Joint Patent      Rights” shall mean all patents and/or patent applications for Joint      Inventions.                                                                                                                                                                                                                                                                                                                                                                                                                             |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1.13   |             “Know-How” shall      mean, without limitation, all trade secrets and technology, as well as      non-patented, non-public inventions, improvements, discoveries, formulae,      processes, data, and reagents discovered or developed by HDC, and owned or      legally acquired by or licensed to HDC without restriction on      dissemination and licensing, before or during the Collaboration Term,      whether patentable or not, and which relate to the Field and the use of      Licensed Prostate Markers in the Field. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1.14   |             “Laboratory Developed      Test” shall mean the provision of test results from use of a      Licensed Product or Licensed Products to assay a patient urine or prostate      biopsy sample, to be entered into the medical history record of the      patient providing the urine or prostate biopsy sample.                                                                                                                                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1.15   |             “Licensed      Product(s)” shall mean finished products consisting of one or more      nucleic acid detection reagents for the assay of one or more Prostate      Marker(s) for use in the Field, the manufacture, use, sale or importation      of which, but for the rights granted herein, would infringe a Valid Claim      within Patent Rights.                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1.16   |             “Net Sales”      shall mean:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |           1.16.1          The      amount charged for Licensed Product to a non-Affiliated third party, less      a lump sum of five percent (5%) to cover all usual deductions, such as      cash discounts allowed and taken; amounts for transportation, insurance or      shipping; amounts repaid, credited or rebated for rejections or returns of      Licensed Product; and taxes and duties. Net Sales shall not include      Licensed Products used for clinical trials, research, evaluation of      customer acceptance, charitable or humanitarian donations, commercial      samples or other noncommercial uses as long as Abbott receives no      financial compensation for such use ordonation. |

----

|   |                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                 |           1.16.2          If      the price of Licensed Product sold by Abbott or its Affiliates is      increased to include an amount to cover the amortized cost of an      instrument system or other equipment or the cost of supplying maintenance      for such system or equipment under a Reagent Agreement Plan, Reagent      Rental Plan or other successor similar plan (collectively referred to as      “RAP”),      the Net Sales for such Licensed Product shall be reduced an additional ten      percent (10%).                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                 |           1.16.3          In      the event that Abbott or its Affiliates sells Licensed Product to a third      party together with one or more other products (each a “Combination      Product”), the Net Sales with respect to such Combination Product      shall mean the price of such Combination Product billed to customers, less      the allowances and adjustments above, multiplied by a percentage equal to      the fraction A/(A+B), where A is the stand-alone market value of the      Licensed Product and B is the stand-alone market value of the other      product(s).                                                                                                                                                                                                                            |
|   |                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                 |           1.16.4          The      amount charged for Laboratory Developed Test to a non-Affiliated third      party, less (i) any shortfall in the reimbursement amount from the amount      charged, and (ii) a lump sum of five percent (5%) to cover all usual      deductions, such as cash discounts allowed and taken; amounts for      transportation, insurance or shipping; amounts repaid, credited or rebated      for rejections or returns of Licensed Product; and taxes and duties. Net      Sales shall not include Laboratory Developed Tests used for clinical      trials, research, evaluation of customer acceptance, charitable or      humanitarian donations, commercial samples or other noncommercial uses as      long as Abbott receives no direct financial compensation for such use or      donation. |
|   |                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.17   |             “Patent Rights”      shall mean: |
|   |                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                 |           1.17.1          all      patent(s) and/or patent applications listed in Exhibit A hereto that are      owned or controlled by HDC as of the Effective Date that are applicable to      the use of the Licensed Prostate Markers in the Field;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|   |                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                 |           1.17.2          any      additional patent and/or patent application(s) which, after the Effective      Date and during the Collaboration Term, are solely owned or controlled by      HDC and are free to be licensed and/or sublicensed by HDC and that are      applicable to the Field (for the avoidance of doubt, such additional      patent and/or patent application(s), including, without limitation, (a)      patents and applications acquired or licensed by HDC from third parties      that are applicable to the Field, and (b) such patents and applications      covering New Inventions owned solely by HDC that are applicable to the      Field; and                                                                                                                                                  |

----

|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |           1.17.3          any      and all divisions, continuations, continuations-in-part, renewals,      reissues, extensions and supplemental protection certificates of any of      the patent applications and patents described in the foregoing clauses of      this Paragraph 1.17. |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                            |
| 1.18                                                   |             “Licensed      Prostate Markers” shall mean one or      more of the nucleic acid detection targets identified in Exhibit B that      are present in a urine or prostate biopsy sample useful for the diagnostic      identification, classification, therapeutic response prediction or      monitoring of prostate cancer.                                                                                                                                                                                                                                                                                                                                           |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                            |
| 1.19                                                   |             “Research      Application” shall mean use of a Licensed Product or component      thereof for research and clinical research applications. For purposes      herein, the performance of a clinical trial using a Licensed Product      during the Collaboration shall be deemed a Research      Application.                                                                                                                                                                                                                                                                                                                                                         |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                            |
| 1.20                                                   |             “FDA Submission      Plan” shall mean the plan for the Collaboration attached hereto as      Exhibit      C.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.21                                                   |             “RUO” shall mean      “research use only”, as defined in United States Code of Federal      Regulations, Title 21, Paragraph 809.10(c)(2)(i).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.22                                                   |             “Territory”      shall mean all the countries in the world.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.23                                                   |             “Utility” means      the application for a Licensed Product, being (a) RUO, (b) an ASR, or (c)      an IVD for any medical utility.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.24                                                   |             “Valid Claim”      shall mean any claim of an issued and unexpired patent within Patent      Rights or Joint Patent Rights exclusively licensed to Abbott, which claim      has not been held invalid or unenforceable by a non-appealable decision of      a court or governmental agency having competent    jurisdiction.                                                                                                                                                                                                                                                                                                                                          |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                            |
| Article 2 - The Collaboration, Materials and      Data |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                            |
| 2.1                                                    |             Collaboration.      During the Collaboration Term and pursuant to the FDA Submission Plan,      Abbott and HDC agree to collaborate on the performance of the necessary      validation studies and clinical trial(s), and the preparation of and      submission to the U.S. Food and Drug Administration (“FDA’) of either a      510(k) or PMA application seeking the necessary authorization from the FDA      for the U.S. marketing, use and sale with associated claims of medical      utility of a prostate cancer diagnostic assay (the “Collaboration”).      For purposes of the Collaboration, the parties acknowledge and agree      that: |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |           2.1.1          The      FDA Submission Plan specifies the responsibilities of the parties for the      clinical trial activities, and may be modified only by a writing executed      by both parties;and                                                                         |

----

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |           2.1.2          Initially,      Abbott will be solely responsible for the preparation and submission of      the 510(k) or PMA application to the FDA. Abbott will provide a draft of      the submission to HDC for its comment at least thirty (30) days before the      actual filing with the FDA. However, the parties may agree in writing to a      change in the allocation of responsibility. In this event, any such      writing will modify the FDA Submission Plan to establish each party’s      responsibilities and whether any additional time or funding is      required. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|   | During      the Collaboration Term, HDC agrees to exclusively collaborate with Abbott      on the performance of the clinical trials and submission to the      FDA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 2.2    |             Exchange of      Materials. During the Collaboration Term, HDC will provide      materials (“HDC      Materials”), including, without limitation, test reagent samples      and clinical samples, to Abbott, and Abbott will provide materials,      including, without limitation, test reagents and clinical samples      necessary to complete the Collaboration (collectively, “Abbott      Materials”) to HDC for the purposes described in the FDA Submission      Plan. Each shall do so at its sole cost and expense. The parties shall      comply with all applicable laws, rules and regulations in the packaging      and shipment of the HDC Materials and Abbott Materials, as applicable      (collectively, “Materials”).      Abbott Materials are and shall remain the sole property of Abbott. HDC      Materials are and shall remain the sole property of HDC. Each party shall      use Materials of the other party solely for the Collaboration and shall      not provide them to any third party for any purpose without the other      party’s prior written consent. Materials shall not be used for purposes of      reporting of patient results, except in the course of a clinical trial      whose protocol expressly provides for such reporting. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 2.3    |             Additional and New      Prostate Markers. Abbott and HDC may each separately bring      additional prostate markers (“Additional Prostate Markers”) into the      Collaboration for investigation in combination with one or more of the      Licensed Prostate Markers identified in Exhibit B. The parties may also      decide to collaborate on discovery of new prostate markers (“New Prostate      Markers”), with either Abbott or HDC providing urine or tissue samples      that may exhibit such New Prostate Markers. Any such New Prostate Markers      discovered in the Collaboration will be jointly owned by Abbott and HDC      and subject to the provisions of Paragraphs 8.5 and 8.6      hereof.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 2.4    |             Disclosure of      Data. All data and other relevant information generated by a party      pursuant to the Collaboration shall be promptly and fully disclosed to the      other party, and shall be freely usable for internal use and any      regulatory submission by the other party subject to the confidentiality      provisions of Article 7 and intellectual property provisions of Article      8.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 2.5    |             Reporting. At      regular intervals to be determined and documented by the parties, each      party shall submit progress and other written status reports as reasonably      requested by the other party. Additionally, the parties shall hold regular      meetings, alternating between their respective headquarters, at least      quarterly, to review and discuss suchprogress.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

----

|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Article 3 - Payments                        |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 3.1                                         |             Signing      Fee. Promptly after execution of this Agreement by both      parties, Abbott shall pay to HDC a one-time Signing Fee of      One-Hundred-Thousand U.S. Dollars ($100,000.00). This Signing Fee shall be      non-refundable and non-creditable towards royalties.                                                                                                              |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 3.2                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Phase 1 and 2      Completion Milestone Fee.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                     3.2.1          Upon      completion of both Phases 1 and 2 described in the FDA Submission Plan,      Abbott shall pay to HDC a one-time Phase 1 and 2 Completion Milestone Fee      of Two-Hundred-Fifty-Thousand U.S. Dollars ($250,000.00). This Phase 1 and      2 Completion Milestone Fee shall be non-refundable and non-creditable      towards royalties. |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 3.3                                         |             Phase 3 and 4      Completion Milestone Fee. Upon completion of both Phases 3 and 4      described in the FDA Submission Plan, Abbott shall pay to HDC a one-time      Phase 3 and 4 Completion Milestone Fee of Two-Hundred-Fifty-Thousand U.S.      Dollars ($250,000.00). This Phase 3 and 4 Completion Milestone Fee shall      be non-refundable and non-creditable towards royalties. |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 3.4                                         |             FDA      Submission Milestone Fee. Promptly after the      filing by Abbott with the FDA of either a 510(k) or PMA submission, Abbott      shall pay to HDC a one-time FDA Submission Fee of Five-Hundred-Thousand      U.S. Dollars ($500,000.00). This Fee shall also be irrevocable and      non-creditable against any royalty obligation.                                              |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 3.5                                         |             FDA      Approval Fee. Promptly after the      receipt by Abbott of a written notification from the FDA of the approval      of the applicable 510(k) or PMA submission, Abbott shall pay to HDC a      one-time FDA Approval Fee of Five-Hundred-Thousand U.S. Dollars      ($500,000.00). This Fee shall also be irrevocable and non-creditable      against any royalty obligation.      |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Article 4 - License Terms and      Royalty. |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 4.1                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                | License      Grant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4.1.1.          Exclusive      License: HDC hereby grants Abbott an exclusive, worldwide, royalty-bearing      license and right to make, have made, use, sell and import Licensed      Products, with the right to sublicense, under Patent Rights, under HDC’s      interest in Joint Patent Rights and Know-How. The exclusive license      granted herein shall be exclusive even as to HDC with respect to the      making, have made, sale and import of Licensed  Products.   |

----

|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                               |                      4.1.2      Co-Exclusive License: HDC hereby grants Abbott a, co-exclusive, worldwide,      royalty-bearing license for the performance of Laboratory Developed Tests,      including the right to make and have made and import Licensed Products      used in the performance of Laboratory Developed Tests, which co-exclusive      license will be shared with the co-licensees identified in Exhibit D      hereto. For as long as this Agreement remains in effect, apart from the      identified co-licensees, HDC shall not retain nor have any right to grant      further sublicenses. |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 4.2    |                                                                                                                                                                                                                                                                                                               | Royalty.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                               |                      4.2.1      For each Licensed Product that is sold by Abbott, Abbott shall pay HDC a      running royalty equal to:                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                               |           (a)      For      Licensed Products with medical utility claims solely for use on prostate      tissue samples, ten percent (10%) of Abbott’s Net Sales of such Licensed      Product; and                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                               |           (b)      For      Licensed Products with medical utility claims solely for use on urine      samples, five percent (5%) of Abbott’s Net Sales of such Licensed      Product                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                               |                     4.2.2      For each Laboratory Developed Test that is sold by Abbott, Abbott shall      pay HDC:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                               |           (a)      a      running royalty equal to ten percent (10%) of Abbott’s Net Sales of such      Laboratory Developed Test performed on a prostate tissue;    or                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                               |           (b)      a      running royalty equal to five percent (5.0%) of Abbott’s Net Sales of such      Laboratory Developed Test performed on a urine sample.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                               |                     4.2.3      Abbott shall make all such payments in respect of running royalties within      forty-five (45) days after the end of each calendar quarter following the      FCS.                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 4.3    |             Sales      Milestones. Upon the sale by Abbott of the specified number of      Licensed Products with a medical utility claim for use on a urine sample,      Abbott agrees to pay HDC, promptly after reaching each Sales      Milestone: |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                               |           (a)      1st      Sales      Milestone: After the sale of Fifty-thousand (50,000) tests      in a calendar year, a one-time 1st Sales Milestone Fee of      Two-Hundred-Thousand U.S. Dollars ($200,000.00);                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                               |           (b)      2nd Sales      Milestone: After the sale of Two-hundred-thousand (200,000) tests in a      calendar year, a one-time 2nd Sales      Milestone Fee of Seven-Hundred-Fifty-Thousand U.S. Dollars ($750,000.00);      and                                                                                                                                                                                                                                                                                                                                                                                                      |

----

|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |           (c)      3rd Sales      Milestone: After the sale of Five-hundred-thousand (500,000) tests in a      calendar year, a one-time 3rd Sales      Milestone Fee of One-Million-Five-Hundred-Thousand U.S. Dollars      ($1,500,000.00);                                                                                                                                              |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                           | The      fees payable under Paragraph 4.3 shall not be creditable against the      running royalty obligation of Paragraph 4.2. Abbott shall make all such      payments under Paragraph 4.2.3 within forty-five (45) days after the end      of each calendar quarter in which the Sales Milestone is      reached.                                                                                                                                                                                                                                                                                                                                                                        |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 4.4                                            |             Required Third Party      Licenses. In the event one or more third party licenses are      required, in Abbott’s reasonable judgment, for Abbott to commercialize a      Licensed Product or Laboratory Developed Test, then Abbott may reduce the      running royalty otherwise payable to HDC for such Licensed Product under      Paragraph 4.2.1 and 4.2.2 by the percentage amount of any running royalty      payable by Abbott under such third-party license; provided, that such      reduction may not be more than fifty percent (50%) of the rates specified      in Paragraphs 4.2.1 and 4.2.2. |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Article 5- Warranties and      Representations |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 5.1                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | HDC. HDC      warrants and represents to Abbott that:                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                     5.1.1      to the best of its knowledge, it has the full legal right to grant Abbott      the licenses to Patent Rights provided herein;                                                                                                                                                                                                           |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                     5.1.2      during the Collaboration Term, HDC will not collaborate with any third      party with respect to any portion of the Collaboration or the development      of any IVD assay covered by Patent Rights;                                                                                                                                   |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                     5.1.3      to the best of its knowledge, no third party is challenging in any      jurisdiction the validity of any of the Patent Rights;                                                                                                                                                                                                          |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                       5.1.4      Exhibit A      lists all patent(s) and/or patent applications owned or controlled by HDC      as of the Effective Date that are applicable to the  Field;                                                                                                                                                                   |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                     5.1.5      it has not received any written or oral communication asserting that the      HDC 4-gene expression assay for prostate cancer to be tested in Phase 1 of      the Validity Studies of the FDA Submission Plan, infringes any      intellectual property right, including any patent right, owned or      controlled by any third party; |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                     5.1.6      it has the corporate power and authority to enter into this Agreement and      the person executing this Agreement on behalf of HDC has been authorized      to do so;                                                                                                                                                                  |

----

|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                     5.1.7      the terms of this Agreement do not conflict with or violate any contract      binding upon HDC; and                                                                                                                                 |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                       5.1.8      it has not      granted and will not grant to any third party, including the co-exclusive      licensees listed in Exhibit D, any rights under Patent Rights to make,      have made, import or sell Licensed Products. |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
| 5.2                                   |             Abbott. Abbott      warrants and represents to HDC that it has the corporate power and      authority to enter into this Agreement, that the person executing this      Agreement on behalf of Abbott has been authorized to do so, and that the      terms of this Agreement do not conflict with or violate any contract      binding upon Abbott. |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
| 5.3                                   |             Limitation of      Liability. IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER      UNDER ANY CIRCUMSTANCES FOR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL OR      SPECIAL DAMAGES, INCLUDING LOST PROFITS, RESULTING FROM THE PARTY’S      PERFORMANCE OR FAILURE TO PERFORM UNDER THIS AGREEMENT.                                           |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
| Article 6 - Term and      Termination |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
| 6.1                                   |             Term. This      Agreement shall become effective on the Effective Date and shall terminate      upon the expiration of the last to expire of Patent Rights licensed      hereunder, unless sooner terminated as provided herein.                                                                                                                     |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
| 6.2                                   |             Termination for      Cause. Either HDC or Abbott may unilaterally terminate this      Agreement upon thirty (30) days written notice to the other in the event      of:                                                                                                                                                                              |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                       6.2.1      the non-terminating party’s insolvency; or                                                                                                                                                                        |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                     6.2.2      a material breach of the Agreement by a party, which breach is not cured      within thirty (30) days of notice of such breach by the other      party.                                                                             |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
| 6.3                                   |             Abbott’s Termination      Right.  Abbott may unilaterally and without cause      terminate this Agreement upon ninety (90) days written notice to      HDC.                                                                                                                                                                          |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
| 6.4                                   |             HDC Termination      Right. HDC may unilaterally terminate this Agreement upon      one-hundred-eighty (180) days written notice to Abbott, which is given      after Abbott has given written notice to HDC that the Completion Standards      of Phase 2 were not met and that Abbott is not proceeding with Phase 3 and      4.                   |
|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |
| 6.5                                   |             Survival.      Paragraph 5.3, Articles 7, 8, 9 (subject to Paragraph 9.4) and 10 shall      survive termination of thisAgreement.                                                                                                                                                                                                                    |

----

|                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |
|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| Article 7 - Confidential      Information |
|                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 7.1                                       |             Confidential      Treatment. A party receiving the Confidential Information (“Receiving      Party”) of the other party (“Disclosing      Party”) agrees to hold that Confidential Information in trust and      confidence for Disclosing Party. A Receiving Party will not use      Confidential Information other than for the purposes of this Agreement.      Each party shall, to the extent applicable hereunder, provide the other      party with patient information as allowed by law and the Receiving Party      shall maintain the confidentiality of all such patient information as      required by law.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 7.2                                       |             Limitation of      Dissemination. A Receiving Party will only disclose Confidential      Information received hereunder, whether oral or in writing, in tangible,      intangible or electronic format, to those persons within the Receiving      Party’s organization or its agents (a) who have a need to know the      Confidential Information in order to perform the Receiving Party’s      obligations under this Agreement, (b) who have been informed of the      confidential nature of the Confidential Information, and (c) who are      obligated to maintain the confidentiality of the Confidential Information      consistent with the terms of this Agreement.                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 7.3                                       |             Standard of      Care. A Receiving Party will treat the Confidential Information of      the Disclosing Party with the same care as the Receiving Party’s own      proprietary information of like kind.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 7.4                                       |             Handling of      Information. A Receiving Party shall not (a) reverse engineer or      otherwise exploit the Confidential Information in violation of this      Agreement, and (b) remove or export from the United States or re-export      any of such Confidential Information or any direct product thereof except      in compliance with and with all licenses and approvals required under      applicable export laws and regulations, including, without limitation,      those of the U.S. Department of Commerce.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 7.5                                       |             Compelled      Disclosure. In the event that a Receiving Party is ordered by a      court of competent jurisdiction or is compelled by law, order or      regulation of a governmental agency or by subpoena to disclose all or any      portion of the Confidential Information of the Disclosing Party to a third      party, the Receiving Party shall give the Disclosing Party prompt notice      of such order or subpoena, together with a copy thereof, so that the      Disclosing Party may seek an appropriate protective order, if applicable.      If, in the absence of a protective order, the Receiving Party is      nonetheless compelled to disclose Confidential Information, the Receiving      Party may disclose such information without liability hereunder; provided,      however, that the Receiving Party gives the Disclosing Party notice of the      Confidential Information to be disclosed as far in advance of its      disclosure as is practicable and the Receiving Party uses its best efforts      to obtain assurances that confidential treatment will be accorded to such      ConfidentialInformation. |

----

|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 7.6                    |             Return of Confidential      Information. Upon termination of this Agreement, the Receiving      Party will return to the Disclosing Party or destroy all written      Confidential Information, as well as any copies thereof, and will promptly      destroy all memoranda, notes and other writings (whether in tangible,      intangible or electronic format) prepared by the Receiving Party or on the      Receiving Party’s behalf based upon the Confidential Information of the      Disclosing Party, except that the Receiving Party may retain one (1) copy      of such Confidential Information for archival purposes, which copy shall      be subject to obligations set forth herein. The Receiving Party shall also      provide the Disclosing Party with a certificate of an appropriate      representative of the Receiving Party to the effect that the Receiving      Party has fully complied with the requirements of this      Paragraph. |
|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 7.7                    |             Injunctive      Relief. Receiving Party acknowledges that the Confidential      Information of Disclosing Party has been developed by Disclosing Party      with substantial effort and at substantial cost and therefore has value to      Disclosing Party, and that the breach of any of the provisions of this      Agreement could cause Disclosing Party irreparable injury for which no      adequate remedy at law exists. Accordingly, Disclosing Party shall have      the right, in addition to any other rights it may have to seek from any      court having jurisdiction a temporary or permanent restraining order or      injunction restraining or enjoining Receiving Party from any violation of      this Agreement.                                                                                                                                                                                                                                  |
|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Article 8 - Inventions |
|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 8.1                    |             Ownership of Existing      Inventions. Existing inventions and technologies of HDC and      Abbott as of the Effective Date (including, without limitation, Licensed      Prostate Markers and Additional Prostate Markers that each separately      bring to the Collaboration) shall respectively remain the sole and      separate property of HDC and Abbott and the ownership thereof shall not be      affected by this Agreement. Except for the license granted Abbott      hereunder, neither party shall have any claims to or rights in such      existing inventions and technologies of the otherparty.                                                                                                                                                                                                                                                                                                                                                       |
|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 8.2                    |             Ownership of New      Inventions. Any new invention, development or discovery relating to      the Field or New Prostate Markers for the Field conceived, made or reduced      to practice by either party as part of the Collaboration, the FDA      Submission Plan or with the use of Materials of the other party (each a      “NewInvention”) shall be promptly      disclosed in writing to the other party. Each party shall retain sole      ownership in each Invention made solely by that party.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 8.3                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Patent Prosecution and      Maintenance. |
|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |
|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                     8.3.1      HDC shall pay all costs associated with the filing, prosecution and      maintenance of patent applications and issued patents within the Patent      Rights. |

----

|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                     8.3.2      HDC shall notify Abbott of any change in status of patents and/or patent      applications listed in Exhibit A and      of the filing of any patent applications within the scope of the Patent      Rights within sixty (60) days of any such change. HDC shall update Exhibit A at      least annually to reflect any such changes. In the event any of the Patent      Rights shall become involved in an opposition or interference proceeding,      HDC shall manage the proceeding, at its own expense, and shall keep Abbott      informed of the status of any such proceeding and may consider Abbott’s      views in formulating HDC’s strategy in the proceeding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |   |                     8.3.3      For New Inventions owned solely by HDC, HDC shall prepare, apply for and      maintain issued patents for such New Inventions throughout the Territory      in such countries and in such manner as HDC shall determine after      reasonable consideration of the views of Abbott.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |   |                     8.3.4      If HDC elects not to file a patent application for a New Invention solely      owned by HDC or to abandon an existing issued patent or pending patent      application within the Patent Rights or do so in any particular      jurisdiction within the Territory, HDC shall notify Abbott within a time      sufficient for Abbott to familiarize itself with the case and make a      decision before abandoning or failing to pursue the relevant issued patent      or pending application. Abbott shall have thirty (30) days from the date      of such notice within which it may notify HDC that Abbott has elected to      assume the obligation and costs of filing and prosecuting or maintaining      such patent application or issued patent. If Abbott elects to assume such      obligation and costs, HDC shall assign its rights in the relevant patent      application or issued patent to Abbott for only the affected      jurisdiction(s); provided, however, that such assignment shall be coupled      with the grant by Abbott to HDC of a fully-paid, nonexclusive license,      without the right to sublicense, in the assigned patent application or      issued patent for internal research purposes only. Any patent application      or issued patent assigned to and maintained by Abbott provided in this      subparagraph shall not be considered Patent Rights under this Agreement      and Abbott shall have no royalty or fee obligations to HDC for Abbott’s      commercial use under such patent applications or issued      patents. |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 8.4    |   | Joint      Inventions.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |   |                     8.4.1      Each Joint Invention shall be jointly owned by the parties and each party      shall have an undivided interest in such Joint Inventions and any Joint      Patent Rights resulting therefrom, including the rights to commercialize      Joint Inventions and grant licenses to third parties under the Joint      Patent Rights. Inventorship for Joint Patent Rights shall be determined in      accordance with U.S. patentlaw.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

----

|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                     8.4.2      Neither party will file applications for U.S. or foreign patents for a      Joint Invention without first consulting the other party. In the event      that both parties agree to file an application for a patent for a Joint      Invention, the parties will share equally all costs associated with      filing, prosecuting, and maintaining Joint Patent Rights directed to any      Joint Invention. The parties will mutually agree which of them will be      responsible for filing, prosecution, and maintenance of a particular      patent application or patent based upon the relative contribution of each      party to the related Joint Invention.                                                                                                                                                                                                                                                                                               |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |   |                     8.4.3      The filing party shall make commercially reasonable efforts to minimize      the cost of the filing and prosecution of patent applications for Joint      Inventions and neither shall charge the other for overhead costs      associated with prosecution undertaken by employed, in-house patent      counsel of the filing party. The filing party shall promptly provide the      non-filing party with copies of papers regarding the prosecution of such      applications (including, without limitation, all patent office actions,      any response to any office action affecting the scope or nature of the      Joint Invention) and will use commercially reasonable efforts to consult      with the non-filing party regarding its interest in the application and      seek claims reasonably consistent with the interests of the non-filing      party prior to making any such claims or responding to any office action      relating thereto. |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |   |                     8.4.4      The non-filing party agrees to provide all reasonable assistance and      cooperation to the filing party, including the execution of      documents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |   |                     8.4.5      Either party may elect at any time not to participate in the filing of a      patent application or maintaining an issued patent for a Joint Invention      by giving notice to the other and assigning all of its rights in such      Joint Invention (including, without limitation, all related Joint Patent      Rights) to the other party. The party making such election shall have no      further obligations to undertake or underwrite the cost, as the case may      be, to prosecute, maintain, and enforce any such Joint Patent Right,      except as to costs and expenses that have accrued prior to such      assignment.                                                                                                                                                                                                                                                                                                                          |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |   |                     8.4.6      Each party will bring to the attention of the other party any third party      infringement of any patent for a Joint Invention of which it becomes      aware. Neither party will enforce any U.S. or foreign patents for a Joint      Invention against a third party without the prior written consent of the      other party, which consent shall not be unreasonably withheld or delayed.      In the event that both parties agree to enforce a patent for a Joint      Invention, the parties will use good faith efforts to determine which      party will be responsible for enforcement of such Joint Patent Rights      against such third party infringers and apportion the costs of enforcement      based upon the commercial interest of each party to the infringing      activity. The parties will apportion any recoveries based upon their      contributions to the cost of enforcing such  patent.                                          |

----

|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                     8.4.7      Neither party will grant a license to any third party to any U.S. or      foreign patents for a Joint Invention without the prior written consent of      the other party. In the event that either party grants a license to a      patent for a Joint Invention, the parties will share equally in the gross      revenues, including, but not limited to, license fees and royalties,      realized for the license to the Joint Invention by the licensing party.      Payments shall be made within forty-five (45) days after the end of each      calendar quarter and accompanied by a report, setting forth the gross      amounts received from the license). Upon reasonable request, the reporting      party shall provide the requesting party copies of applicable reports due      from the license under the license relating to royalties payable to the      licensor party. Such reports shall constitute the licensor party’s      Confidential Information and shall be returned to the licensor party after      the requesting party has had a reasonable opportunity to review the      reports. |
|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                     8.4.8      If after good faith negotiations the parties cannot reach agreement as to      any dispute regarding Joint Inventions and Joint Patent Rights, the      dispute may be submitted to Alternative Dispute Resolution as provided for      in Paragraph 10.12.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Article 9-  Indemnification |
|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 9.1                         |             HDC. HDC shall      indemnify, defend and hold harmless Abbott and its Affiliates, employees,      officers, directors and agents from and against any suit, proceeding,      claim, liability, loss, damage, costs or expense, including reasonable      attorneys’ fees, which Abbott may hereinafter incur, suffer, or be      required to pay arising out of or resulting from (a) any breach by HDC of      the representations and warranties set forth in Paragraph 5.1 of this      Agreement, and (b) any injury or other harm caused solely by HDC in      carrying out its obligations pursuant to the  Collaboration.       |
|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 9.2                         |             Abbott. Abbott      shall indemnify, defend, and hold harmless HDC and its Affiliates,      employees, officers, directors and agents from and against any suit,      proceeding, claim, liability, loss, damage, costs or expense, including      reasonable attorneys’ fees, which HDC may hereinafter incur, suffer or be      required to pay arising out of or resulting from (a) any breach by Abbott      of the representations and warranties set forth in Paragraph 5.2 of this      Agreement, and (b) any injury or other harm caused solely by Abbott in      carrying out its obligations pursuant to the  Collaboration. |
|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 9.3                         |             Notice and      Cooperation. With respect to any claim for which a party seeks      indemnification from the other hereunder, the party seeking      indemnification shall provide prompt notice to the other of the claim for      which indemnification is sought, shall provide reasonable cooperation and      assistance to the indemnifying party in the defense of such claim, and      shall not settle or otherwise compromise such claim without the      indemnifying party’s prior writtenconsent.                                                                                                                          |

----

|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 9.4                         |             Termination of      Indemnification Obligations. All obligations for indemnification on      the part of parties hereto shall expire two (2) years from the date of      termination of this Agreement, except with respect to claims for      indemnification made prior to the end of such two (2) year      period.                                                                                                       |
|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Article 10 -  Miscellaneous |
|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |   |
| 10.1                        |             Notices. Any      notice, report, payment or statement required or permitted under this      Agreement shall be considered to be given in writing when sent by      certified mail (return receipt requested), postage prepaid, or faxed then      mailed, or if sent via courier and addressed to the party for whom it is      intended at its address of record. The record addresses of the parties are      as follows: |

|   | If      to HDC:                                                                                                                                                                                                                                                               | Chairman      and CEO                               |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
|   |                                                                                                                                                                                                                                                                          | Health      Discovery Corporation                   |
|   |                                                                                                                                                                                                                                                                          | 2      East Bryan Street, Suite #601                |
|   |                                                                                                                                                                                                                                                                          | Savannah,      GA 31401                             |
|   |                                                                                                                                                                                                                                                                          | FAX:      (912) 443-1989                            |
|   |                                                                                                                                                                                                                                                                          |                                                |
|   |                                                                                                                                                                                                                                                                          | with      a copy to:                                |
|   |                                                                                                                                                                                                                                                                          | Procopio,      Cory, Hargreaves & Savitch LLP   |
|   |                                                                                                                                                                                                                                                                          | 530      B Street, Suite 2100                       |
|   |                                                                                                                                                                                                                                                                          | San      Diego, CA 92101                            |
|   |                                                                                                                                                                                                                                                                          | Fax:      619-744-5478                              |
|   |                                                                                                                                                                                                                                                                          | Attn:      Eleanor M. Musick, Esq.                  |
|   |                                                                                                                                                                                                                                                                          |                                                |
|   | If      to Abbott:                                                                                                                                                                                                                                                            | Director,      Licensing & Business Development |
|   |                                                                                                                                                                                                                                                                          | Abbott      Molecular Inc.                          |
|   |                                                                                                                                                                                                                                                                          | 1300      E. Touhy Ave, 3C                          |
|   |                                                                                                                                                                                                                                                                          | Des      Plaines, IL 60018-3315                     |
|   |                                                                                                                                                                                                                                                                          | Fax:      (224) 361-7054                            |
|   |                                                                                                                                                                                                                                                                          |                                                |
|   |                                                                                                                                                                                                                                                                          | With      a copy to:                                |
|   |                                                                                                                                                                                                                                                                          |                                                |
|   |                                                                                                                                                                                                                                                                          | VP,      Domestic Legal                             |
|   |                                                                                                                                                                                                                                                                          | Abbott      Laboratories                            |
|   |                                                                                                                                                                                                                                                                          | Dept.      322, Bldg. AP-6A                         |
|   |                                                                                                                                                                                                                                                                          | 100      Abbott Park Road                           |
|   |                                                                                                                                                                                                                                                                          | Abbott      Park, IL 60064-6049                     |
|   |                                                                                                                                                                                                                                                                          | Fax:      (847) 938-1206                            |
|   |                                                                                                                                                                                                                                                                          |                                                |
| 10.2   |             Compliance with      Laws. The parties will comply with applicable laws in conducting      the Collaboration, including, if applicable, any requirements for      Institutional Review Boardapproval. |

----

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.3   |             No Partnership.      The parties do not intend to create any partnership, joint venture or      agency relationship under this Agreement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 10.4   |             Use of a Party’s      Name. Neither party will, without the prior written consent of the      other party, (a) use in advertising, publicity or otherwise, the name of      any employee or agent, any trade-name, trademark, trade device, service      mark, symbol, or any abbreviation, contraction or simulation thereof owned      by the other party, or (b) represent, either directly or indirectly, that      any product or service of the other party is a product or service of the      representing party or that it is made in accordance with or utilizes the      information or documents of the other party.                                                                                             |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 10.5   |             Entire      Agreement. This Agreement and all attached Exhibits contain the      entire agreement and understanding between the parties as to its subject      matter. It merges all prior discussions between the parties and neither      party will be bound by conditions, definitions, warranties,      understandings, or representations concerning such subject matter except      as provided in this Agreement or as specified on or subsequent to the      Effective Date of this Agreement in a writing signed by properly      authorized representatives of the parties. This Agreement may only be      modified by written agreement duly signed by persons duly authorized on      behalf of both HDC and Abbott. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 10.6   |             Assignment.      This Agreement shall be binding upon and inure to the benefit of the      parties hereto and their successors and assigns. Notwithstanding the      foregoing, neither party may assign, delegate or otherwise transfer any of      its rights or obligations under this Agreement without the prior written      consent of the other party which will not be unreasonably withheld;      provided, however, that either party may transfer its rights and      obligations without the consent of the other party (a) upon a Change in      Control, or (b) to any of its Affiliates provided that the assigning party      guarantees the performance of its Affiliate.                                        |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 10.7   |             Waiver. The      failure of a party in any instance to insist upon the strict performance      of the terms of this Agreement will not be construed to be a waiver or      relinquishment of any of the terms of this Agreement, either at the time      of the party’s failure to insist upon strict performance or at any time in      the future, and such terms will continue in full force and      effect.                                                                                                                                                                                                                                                                                                             |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 10.8   |             Severability.      Each clause of this Agreement is a distinct and severable clause and if      any clause is deemed illegal, void or unenforceable, the validity,      legality or enforceability of any other clause or portion of this      Agreement will not be affected thereby.                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 10.9   |             Governing Law.      The rights and obligations of this Agreement will be governed and      construed in accordance with the laws of the State of Delaware, United      States of America (excluding and without regard to its or any other      jurisdiction’s rules concerning conflicts of  laws).                                                                                                                                                                                                                                                                                                                                                                                                                         |

----

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.10  |             Titles. All      titles and articles headings contained in this Agreement are inserted only      as a matter of convenience and reference. They do not define, limit,      extend or describe the scope of this Agreement or the intent of any of its      provisions.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 10.11  |             Alternative Dispute      Resolution. The parties recognize that a dispute as to certain      matters (other than those specified in Exhibit E) may      arise from time to time during the term of this Agreement which relates to      either party's rights and/or obligations under this Agreement. The parties      agree to resolve any such dispute exclusively according to the provisions      set forth in Exhibit E.      Notwithstanding the foregoing, any dispute between the parties relating to      patent validity and enforceability shall not be resolved under this      Paragraph 10.11, nor by any other form of alternative dispute resolution,      but rather by litigation in U.S. Federal Court. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 10.12  |             Counterparts.      This Agreement may be executed in one or more counterparts, each of which      shall constitute an original, and all of which together shall constitute      one and the same instrument.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   | In      witness thereof, HDC and Abbott have duly executed this Agreement as of      the EffectiveDate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

| ABBOTT      MOLECULAR INC. | HEALTH      DISCOVERY CORPORATION |
|----------------------------|-----------------------------------|
|                       |                              |   |   |   |   |
| By                    | /s/      Stafford O’Kelly   |   | By  | /s/      Stephen D. Barnhill, M.D. |   |
|                       |                              | Stafford      O’Kelly |   |   | Stephen      D. Barnhill, M.D. |
|                       |                              | President |   |   | Chairman      and CEO |

| Date | January      30, 2009 |   | Date | January      30, 2009 |   |
|------|-----------------------|--------|------|-----------------------|--------|

----

|           |   |                                          |   |                                                                           |
|----------------|--------|-----------------------------------------------|--------|--------------------------------------------------------------------------------|
| Country/Region |   | Patent/      Publication/Application      No. |   | Title                                                                          |
| U.S.           |   | 7,117,188                                     |   | Method      of Identifying Patterns in Biological Systems and Uses    Thereof  |
| U.S.           |   | 12/025,724                                    |   | Biomarkers      Upregulated in Prostate Cancer                                 |
| U.S.           |   | 12/242,264                                    |   | Biomarkers      Overexpressed in Prostate Cancer                               |
| U.S.           |   | 12/327,823                                    |   | Methods      for Screening, Predicting and Monitoring ProstateCancer           |
| U.S.           |   | 12/349,437                                    |   | Methods      for Screening, Predicting and Monitoring ProstateCancer           |
| Australia      |   | 2002253879                                    |   | Methods      of Identifying Patterns in Biological Systems and Uses    Thereof |
| Canada         |   | 2,435,254                                     |   | Method      of Identifying Patterns in Biological Systems and Uses    Thereof  |
| Europe         |   | 1459235                                       |   | Method      of Identifying Patterns in Biological Systems and Uses    Thereof  |
| Japan          |   | 2002-560076                                   |   | Method      of Identifying Patterns in Biological Systems and Uses    Thereof  |
| Europe         |   | 1828917                                       |   | Biomarkers      for Screening, Predicting, and Monitoring Prostate  Disease    |

----

|   |   |                    |   |                   |   |       |   |            |   |                                      |   |                                                                                                                                                                                                                                                                                                                                         |
|--------|--------|-------------------------|--------|------------------------|--------|------------|--------|-----------------|--------|-------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Num    |   | ArchivalUnigene      ID |   | CurrentUnigene      ID |   | Symbol     |   | Affy      probe |   | Pathway                                   |   | Target      Description                                                                                                                                                                                                                                                                                                                      |   |
|   |   |                    |   |                   |   |       |   |            |   |                                      |   |                                                                                                                                                                                                                                                                                                                                         |
| 12337  |   | Hs.7780                 |   | Hs.480311              |   | DKFZp564   |   | 212412_at       |   | Unknown                                   |   |   Consensus      includes gb:AV715767 /FEA=EST /DB_XREF=gi:10797284 /DB_XREF= est:AV715767      /CLONE=DCBATH02      /UG=Hs.7780 Homo sapiens mRNA; cDNA DKFZp564A072 (from clone      DKFZp564A072)                                                                                                                               |
|   |   |                    |   |                   |   |       |   |            |   |                                      |   |                                                                                                                                                                                                                                                                                                                                         |
| 9373   |   | Hs.21293                |   | Hs.492859              |   | UAP1/AGX-1 |   | 209340_at       |   | Aminosugarmetabolism                      |   |   gb:S73498.1      /DEF=Homo sapiens AgX-1 antigen mRNA; complete cds. /FEA=mRNA /PROD=AgX-1      antigen /DB_XREF=gi:688010 /UG=Hs.21293 UDP-N-acteylglucosamine      pyrophosphorylase 1 /FL=gb:AB011004.1 gb:NM_003115.1      gb:S73498.1                                                                                       |
|   |   |                    |   |                   |   |       |   |            |   |                                      |   |                                                                                                                                                                                                                                                                                                                                         |
| 876    |   | Hs.79037                |   | Hs.476231              |   | HSPD1      |   | 200807_s_at     |   | Mitochondrialcontrol      ofapoptosis     |   |   gb:NM_002156.1      /DEF=Homo sapiens heat shock 60kD protein 1 (chaperonin) (HSPD1); mRNA.      /FEA=mRNA /GEN=HSPD1 /PROD=heat shock 60kD protein 1 (chaperonin)      /DB_XREF=gi:4504520 /UG=Hs.79037 heat shock 60kD protein 1 (chaperonin)      /FL=gb:BC002676.1 gb:BC003030.1 gb:M34664.1 gb:M22382.1      gb:NM_002156.1 |
|   |   |                    |   |                   |   |       |   |            |   |                                      |   |                                                                                                                                                                                                                                                                                                                                         |
| 1961   |   |                    |   | Hs.75432               |   | IMPDH2     |   | 201892_s_at     |   | de      novoguaninenucleotidebiosynthesis |   |   gb:NM_000884.1      /DEF=Homo sapiens IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2);      mRNA. /FEA=mRNA /GEN=IMPDH2 /PROD=IMP (inosine monophosphate)      dehydrogenase 2 /DB_XREF=gi:4504688 /UG=Hs.75432 IMP (inosine      monophosphate) dehydrogenase 2 /FL=gb:J04208.1    gb:NM_000884.1                          |

----

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |   |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|   | I.          Costs      and Performance Site for Phase 1 and 2:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   | Abbott      and HDC agree to have the experimental testing of Phase 1 and 2 performed      at *, with *, as the principal investigator. HDC is negotiating an      experimental testing agreement in place with * that will cover the      performance of Phase 1 and 2. HDC warrants that it will have the right      under the agreement with * to transfer the data resulting from Phase 1 and      2 testing to Abbott and that Abbott will have the royalty-free right to      use the data in any regulatory submission. Abbott shall be responsible for      payment to HDC of *’s actual costs for performance of the Phase 1 and 2      experimental testing, up to a maximum of One-Hundred-Thousand Dollars      ($100,000.00). HDC shall be responsible for payment to * of all costs in      excess of the One-Hundred-Thousand Dollars ($100,000.00). Abbott shall      make the payments to HDC within thirty (30) days of receipt of invoice      from HDC, and HDC shall make the payment to * for any excess costs within      thirty (30) days of receipt of notice from  Abbott. |

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | The      objective of this phase of the study is to develop the HDC 4-gene      expression assay in urine. The assay may be done in up to four separate      RT-PCR reactions or in one or more multiplex groupings. The urine sediment      containing the tumor cells, obtained after centrifugation, will be      extracted to obtain mRNA. Primers and probes for real time, RT-PCR assays      will be developed by HDC for the 4 genes of interest and for 5 potential      candidates to serve as the reference (housekeeping) genes. While the B2M      was the most stable gene in the preliminary studies, a re-evaluation of      all five gene candidates will be required. One or more may be selected as      the reference gene(s) for the 4-gene assay. In this first phase of the      study, prostate cancer cells obtained from tissue culture will be used,      and preparations of tissue culture cells will be spiked into urine      containing RNAse enzyme inhibitors. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|   | The      collection of patient urine, serum and tissue specimens for both Phase 1      and 2 will be initiated and the specimens properly stored beginning      immediately upon IRB approval. This will allow specimen collection to be      completed in advance of the start of Phase2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

----

|   | Phase 1 Feasibility Results Completion Standard:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   | The      successful completion of Phase I will be the demonstration of      “Feasibility” for the assay, and will be determined by Abbott in its sole      discretion. Feasibility will be demonstrated by showing an ability of the      assay to identify prostate cancer as present based on an elevated      expression of the genes of interest in prostate cells in urine specimens      compared to the background expression levels of the normal epithelial      cells, using a cut-off that will have *% sensitivity and *%      specificity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   | III.      Phase 2 (expected duration 2 months): Assess the utility of the 4-gene      urine test for prostate cancer detection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   | The      objective of the Phase 2 validation study is to determine if the assay can      detect cancer cells in urine from patients with prostate cancer with a      high degree of sensitivity. Urine samples obtained from * patients with      prostate cancer will be tested. The testing will be done on urine samples      obtained pre and post prostatectomy. Greater than or equal to *%      sensitivity on pre-op specimens is expected, with all urine positive      patients becoming negative when tested one month      post-prostatectomy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   | A      control group of * non-prostate cancer subjects will be tested in a      similar fashion on two specimens collected one month apart. One control      group of * subjects will be less than 30 years old and have a serum PSA      value less than 1.0 ng/mL and the second control group will have serum PSA      value greater than 2.5 ng/mL and less than 10ng/mL and will have had one      previous negative biopsy. The HDC 4-gene test developed in Phase 1 will be      performed on these patients before the second biopsy is performed. The      result of the HDC 4-gene test will then be compared to the result of the      second biopsy. Control subjects with low PSA are likely to have no      prostatic enlargement, while subjects with PSA values greater than 2.5      ng/mL will likely have some degree of prostatic enlargement (BPH). All of      the subjects in the control group with a PSA value less than 1ng/mL are      expected to have negative results for the urine gene test. Greater than or      equal to *% specificity is expected. Serum PSA testing will be performed      on all subjects at each time of a urine collection. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   | For      the * cancer subjects, the Gleason Score will be determined and the total      tumor volume obtained from the prostatectomy tissue will be measured. The      urine HDC 4-gene score for low grade (Gleason Score), low volume subjects      as well as those with high grade, high volume cancers will be      compared.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   | In      addition, in the * cancer subjects, cancer cells from the formalin fixed      tissue slide will be obtained by micro dissection after being carefully      identified by the pathologist, and the assay tissue score will be compared      with the respective assay urinescore.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

----

|   | Phase 2 Results Completion      Standard:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | The      successful completion of Phase 2 will be determined by Abbott in its sole      discretion, and will be: (i) the demonstration of performance for the      assay of sensitivity greater than or equal to *% and specificity greater      than or equal to *%, and (ii) demonstration of informative test results      for informative urine specimens collected without DRE (success rate) based      on sufficient quantity of tumor mRNA for evaluation of greater than or      equal to *%. Specificity will be reported against normal and BPH      subjects. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | IV.      Phase 3 and 4 studies (below) will be initiated only upon the review and      acceptance of      Phase 1 & 2 as meeting the Result Completion  Standards.                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | Costs and Performance Site for Phase 3 and      4:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | Abbott      at its sole discretion shall select the institution to perform the Phase 3      and 4 testing. Abbott shall be responsible for negotiating and signing the      test performance agreement with the institution selected. Abbott shall be      responsible for the costs of the selected institution for the performance      of Phase 3 and 4.                                                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | V.      Phase 3 (expected duration 1 month): Determine if DRE performed prior to      collection of urine specimens will increase the sensitivity of prostate      cancer detection.                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | The      effect of the digital rectal examination to enhance the detection rate      will be assessed using urine samples collected from * prostate cancer      patients and * non-cancer patients. This data will determine if a random      urine collection will give a 4-gene test result that is equivalent to a      post-DRE sample.                                                                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | Phase      3 Results Completion Standard:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | Demonstrate      a preferred method of urine specimen collection with a success rate (%      informative) of greater than or equal to the success rate reported for      competitor’s assays (PCA3,*%)                                                                                                                                                                                                                                                                                                                                                              |

----

|   | Phase      4 (expected duration 4 Months): Specificity and Assay Optimization      Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | The      optimal reaction conditions for the urine assay will be developed, and      detection limits and the inter and intra precision for assay will be      established.                                                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | Stability      of the mRNA in urine tumor cells under various storage conditions, i.e. *      and * will be determined and optimal urine collection and storage      conditions will be defined.                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | With      the optimized assay, a preliminary assessment or test specificity of the      4-gene urine test will be accomplished by a) assessing the interference of      leukocytes in urine as a result of inflammation or by blood contamination      of the urine sample by spiking negative and positive urine samples with      leukocytes and b) assessing the tissue specificity of the assay by a      survey of urine samples from * patients with cancer types that could      interfere with the assay, such as bladder, kidney and    others. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | The      mRNA or c-DNA from the phase 1-4 validation studies will be stored at - 70      degrees C for future use in validating any new RT-PCR platform which might      be used in an FDA clearance study.                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | With      the optimized assay, detection of tumors with a range of Gleason scores,      stages, and various patient characteristics (age, ethnic characteristic)      will be evaluated.                                                                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | Phase 4 Results Completion      Standard:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|   | 1)      The test should demonstrate no cross-reactivity with cancer types that      could interfere with the assay, such as bladder, kidney and      others.                                         |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | 2)      The test should demonstrate reproducible performance under specimen      storage/shipping conditions compatible with standard laboratory      workflow.                                      |
|   | 3)      The test should demonstrate utility in a range of patient populations and      tumor characteristics (grade, stage) with a sensitivity and specificity      each greater than or equal to*%. |

----

|   |                                        |                                                                        |
|--------|---------------------------------------------|-----------------------------------------------------------------------------|
|   | Quest      Diagnostics, Inc. (Madison, NJ): |
|   |                                        | Territory:      United States of America, its territories and  possessions. |
|   |                                        | Field:      Laboratory Developed Tests in urine                             |
|   |                                        |
|   | Clarient,      Inc.(Aliso Viejo, CA):       |
|   |                                        | Territory:      Worldwide                                                   |
|   |                                        | Field:      Laboratory Developed Tests in biopsied prostate  tissue         |

----

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.     | To      begin an ADR proceeding, a party shall provide written notice to the other      party of the issues to be resolved by ADR. Within fourteen (14) days after      its receipt of such notice, the other party may, by written notice to the      party initiating the ADR, add additional issues to be resolved within the      same ADR.                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2.     | Within      twenty-one (21) days following receipt of the original ADR notice, the      parties shall select a mutually acceptable neutral to preside in the      resolution of any disputes in this ADR proceeding. If the parties are      unable to agree on a mutually acceptable neutral within such period,      either party may request the President of the CPR Institute for Dispute      Resolution (“CPR”), 366      Madison Avenue, 14th Floor, New York, New York 10017, to select a neutral      pursuant to the followingprocedures: |

|   |           (a)     The      CPR shall submit to the parties a list of not less than five (5)      candidates within fourteen (14) days after receipt of the request, along      with a Curriculum      Vitae for each candidate. No candidate shall be an employee,      director or shareholder of either party or any of their subsidiaries or      affiliates.                                                                                                                                                                                                                                                                            |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|   |           (b)     Such      list shall include a statement of disclosure by each candidate of any      circumstances likely to affect his or her impartiality.                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|   |           (c)     Each      party shall number the candidates in order of preference (with the number      one (1) signifying the greatest preference) and shall deliver the list to      the CPR within seven (7) days following receipt of the list of candidates.      If a party believes a conflict of interest exists regarding any of the      candidates, that party shall provide a written explanation of the conflict      to the CPR along with its list showing its order of preference for the      candidates. Any party failing to return a list of preferences on time      shall be deemed to have no order ofpreference. |

----

|   |           (d)     If      the parties collectively have identified fewer than three (3) candidates      deemed to have conflicts, the CPR immediately shall designate as the      neutral the candidate for whom the parties collectively have      indicated the greatest preference. If a tie should result between two      candidates, the CPR may designate either candidate. If the parties      collectively have identified three (3) or more candidates deemed to have      conflicts, the CPR shall review the explanations regarding conflicts and,      in its sole discretion, may either (i) immediately designate as the      neutral the candidate for whom the parties collectively have indicated the      greatest preference, or (ii) issue a new list of not less than five (5)      candidates, in which case the procedures set forth in subparagraphs 2(a) -      2(d) shall be repeated. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.     | No      earlier than twenty-eight (28) days or later than fifty-six (56) days      after selection, the neutral shall hold a hearing to resolve each of the      issues identified by the parties. The ADR proceeding shall take place at a      location agreed upon by the parties. If the parties cannot agree, the      neutral shall designate a location other than the principal place of      business of either party or any of their subsidiaries or      affiliates. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 4.     | At      least seven (7) days prior to the hearing, each party shall submit the      following to the other party and theneutral:                                                                                                                                                                                                                                                                                                                                                |

|   |           (a)     a      copy of all exhibits on which such party intends to rely in any oral or      written presentation to the neutral;                                                                                                                                                                                       |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |           (b)     a      list of any witnesses such party intends to call at the hearing, and a      short summary of the anticipated testimony of each  witness;                                                                                                                                                                |
|   |                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |           (c)     a      proposed ruling on each issue to be resolved, together with a request for      a specific damage award or other remedy for each issue. The proposed      rulings and remedies shall not contain any recitation of the facts or any      legal arguments and shall not exceed one (1) page per    issue. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |           (d)     a      brief in support of such party’s proposed rulings and remedies, provided      that the brief shall not exceed twenty (20) pages. This page limitation      shall apply regardless of the number of issues raised in the ADR      proceeding.                                                      |

|   | Except      as expressly set forth in subparagraphs 4(a) - 4(d), no discovery shall be      required or permitted by any means, including depositions,      interrogatories, requests for admissions, or production of      documents. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                   |
| 5.     | The      hearing shall be conducted on two (2) consecutive days and shall be      governed by the followingrules:                                                                                                                      |

|   |           (a)     Each      party shall be entitled to five (5) hours of hearing time to present its      case. The neutral shall determine whether each party has had the five (5)      hours to which it is entitled. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |           (b)     Each      party shall be entitled, but not required, to make an opening statement,      to present regular and rebuttal testimony, documents or other evidence, to      cross-examine witnesses, and to make a closing argument. Cross-examination      of witnesses shall occur immediately after their direct testimony, and      cross-examination time shall be charged against the party conducting the      cross-examination.                                                                            |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |           (c)     The      party initiating the ADR shall begin the hearing and, if it chooses to      make an opening statement, shall address not only issues it raised but      also any issues raised by the responding party. The responding party, if      it chooses to make an opening statement, also shall address all issues      raised in the ADR. Thereafter, the presentation of regular and rebuttal      testimony and documents, other evidence, and closing arguments shall      proceed in the same sequence. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |           (d)     Except      when testifying, witnesses shall be excluded from the hearing until      closing arguments.                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |           (e)     Settlement      negotiations, including any statements made therein, shall not be      admissible under any circumstances. Affidavits prepared for purposes of      the ADR hearing also shall not be admissible. As to all other matters, the      neutral shall have sole discretion regarding the admissibility of any      evidence.                                                                                                                                                                        |

| 6.     | Within      seven (7) days following completion of the hearing, each party may submit      to the other party and the neutral a post-hearing brief in support of its      proposed rulings and remedies, provided that such brief shall not contain      or discuss any new evidence and shall not exceed ten (10) pages. This page      limitation shall apply regardless of the number of issues raised in the      ADR proceeding.                                                                                     |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 7.     | The      neutral shall rule on each disputed issue within fourteen (14) days      following completion of the hearing. Such ruling shall adopt in its      entirety the proposed ruling and remedy of one of the parties on each      disputed issue but may adopt one party’s proposed rulings and remedies on      some issues and the other party’s proposed rulings and remedies on other      issues. The neutral shall not issue any written opinion or otherwise      explain the basis of the ruling. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 8.     | The      neutral shall be paid a reasonable fee plus expenses. These fees and      expenses, along with the reasonable legal fees and expenses of the      prevailing party (including all expert witness fees and expenses), the      fees and expenses of a court reporter, and any expenses for a hearing      room, shall be paid asfollows:                                                                                                                                                                          |

|   |           (a)     If      the neutral rules in favor of one party on all disputed issues in the ADR,      the losing party shall pay 100% of such fees and  expenses.                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |           (b)     If      the neutral rules in favor of one party on some issues and the other party      on other issues, the neutral shall issue with the rulings a written      determination as to how such fees and expenses shall be allocated between      the parties. The neutral shall allocate fees and expenses in a way that      bears a reasonable relationship to the outcome of the ADR, with the party      prevailing on more issues, or on issues of greater value or gravity,      recovering a relatively larger share of its legal fees and      expenses. |

----

| 9.     | The      rulings of the neutral and the allocation of fees and expenses shall be      binding, non-reviewable, and non-appealable, and may be entered as a final      judgment in any court having jurisdiction.                                                                                                                                                                                                              |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.    | Except      as provided in paragraph 9 or as required by law, the existence of the      dispute, any settlement negotiations, the ADR hearing, any submissions      (including exhibits, testimony, proposed rulings, and briefs), and the      rulings shall be deemed Confidential Information. The neutral shall have      the authority to impose sanctions for unauthorized disclosure of      Confidential Information. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 11.    | All      disputes referred to ADR, the statute of limitations, and the remedies for      any wrong that may be found, shall be governed by the laws of the State of      Illinois.                                                                                                                                                                                                                                            |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 12.    | The      neutral may not award punitive damages. The parties hereby waive the right      to punitive damages.                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 13.    | The      hearings shall be conducted in the English  language.                                                                                                                                                                                                                                                                                                                                                                |